173 results on '"Miao Mo"'
Search Results
2. Advances in molecular basis of response to immunotherapy for penile cancer: better screening of responders
- Author
-
Da-Ming Xu, Ling-Xiao Chen, Xiao-Yu Zhuang, Hui Han, and Miao Mo
- Subjects
penile cancer ,immunotherapy ,biomarker ,sensitivity ,resistance ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Penile cancer is a rare malignant tumor of the male urinary system. The treatment benefit of standard first-line chemotherapy is not ideal for patients with locally advanced or metastatic lymph nodes. Immunotherapy has brought new treatment strategies and opportunities for patients with penile cancer. At present, clinical studies on immunotherapy for penile cancer have been reported, and the results show that it is effective but not conclusive. With the development of immunotherapy and the progress of molecular research technology, we can better screen the immunotherapy response population and explore new combination treatment regimens to evaluate the best combination regimen and obtain the optimal treatment options, which is also an important research direction for the immunotherapy of penile cancer in the future.
- Published
- 2024
- Full Text
- View/download PDF
3. Adjuvant medial versus entire supraclavicular lymph node irradiation in high-risk early breast cancer (SUCLANODE): a protocol for a multicenter, randomized, open-label, phase 3 trial
- Author
-
Li Zhang, Xin Mei, Zhigang Hu, Bo Yu, Chaoyang Zhang, Yong Li, Kaitai Liu, Xuejun Ma, Jinli Ma, Xingxing Chen, Jin Meng, Wei Shi, Xiaofang Wang, Miao Mo, Zhimin Shao, Zhen Zhang, Xiaoli Yu, Xiaomao Guo, and Zhaozhi Yang
- Subjects
Breast cancer ,Supraclavicular nodal irradiation ,Target volume ,Survival outcome ,Toxicity ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Supraclavicular nodal (SCL) irradiation is commonly used for patients with high-risk breast cancer after breast surgery. The Radiation Therapy Oncology Group (RTOG) and European Society for Radiotherapy and Oncology (ESTRO) breast contouring atlases delineate the medial part of the SCL region, while excluding the posterolateral part. However, recent studies have found that a substantial proportion of SCL failures are located in the posterolateral SCL region, outside of the RTOG/ESTRO-defined SCL target volumes. Consequently, many radiation oncologists advocate for enlarging the SCL irradiation target volume to include both the medial and posterolateral SCL regions. Nevertheless, it remains uncertain whether adding the posterolateral SCL irradiation improves survival outcomes for high-risk breast cancer patients. Methods The SUCLANODE trial is an open-label, multicenter, randomized, phase 3 trial comparing the efficacy and adverse events of medial SCL irradiation (M-SCLI group) and medial plus posterolateral SCL irradiation (entire SCL irradiation, E-SCLI group) in high-risk breast cancer patients who underwent breast conserving-surgery or mastectomy. Patients with pathological N2-3b disease following initial surgery, or clinical stage III or pathological N1-3b if receiving neoadjuvant systemic therapy, are eligible and randomly assigned (1:1) to M-SCLI group and E-SCLI group. Stratification is by chemotherapy sequence (neoadjuvant vs. adjuvant), T stage (T3-4 vs. T1-2), N stage (N1-2 vs. N3), and ER status (positive vs. negative). Other radiation volumes are identical in the two arms, including breast/chest wall, undissected axillary lymph node, and internal mammary node. Advanced intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), or tomotherapy techniques are recommended. Both hypofractionated and conventional fractionation schedules are permitted. The primary end point is invasive disease-free survival, and secondary end points included overall survival, SCL recurrence, local-regional recurrence, distance recurrence, safety outcome, and patient-reported outcomes. The target sample size is 1650 participants. Discussion The results of the SUCLANODE trial will provide high-level evidence regarding whether adding posterolateral SCL irradiation to medial SCL target volume provides survival benefit in patients with high-risk breast cancer. Trial registration ClinicalTrials.gov Identifier: NCT05059379. Registered 28 September 2021, https://www.clinicaltrials.gov/ct2/show/NCT05059379 .
- Published
- 2024
- Full Text
- View/download PDF
4. Induction sintilimab and chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal cancer: a proof-of-concept, single-arm, multicenter, phase 2 trialResearch in context
- Author
-
Dashan Ai, Shengnan Hao, Wenbin Shen, Qibing Wu, Shengjian Zhang, Yun Chen, Qi Liu, Jiaying Deng, Hongcheng Zhu, Ke Chen, Miao Mo, Dayong Gu, Yatian Liu, Zhi Zhang, Guoren Zhou, Jingwen Hu, Zhen Zhang, Jinjun Ye, and Kuaile Zhao
- Subjects
Esophageal cancer ,Chemoradiotherapy ,Immunotherapy ,Radiosensitivity ,Medicine (General) ,R5-920 - Abstract
Summary: Background: Concurrent chemoradiotherapy is the standard nonoperative treatment for locally advanced esophageal squamous cell carcinoma. However, local recurrence is still the main failure pattern, accounting for more than half of all treatment failures, indicating that the sensitivity of radiotherapy still needs to be improved. This trial aimed at demonstrating whether PD-1 inhibitors followed by chemoradiotherapy could promote esophageal tumor vascular normalization, alleviate hypoxia, and thus enhance radiosensitivity and improve local control. Methods: We did a multicenter, single-arm, phase 2 trial in China. Patients with locally advanced esophageal cancer were enrolled in this study. In induction phase, patients received two cycles of sintilimab, paclitaxel and carboplatin once per 21 days. In concurrent phase, patients were treated with five cycles of carboplatin and paclitaxel once per week concurrent with radiotherapy of 50.4Gy delivered in 28 fractions. The primary endpoint was 2-year local control rate. Hypoxia and vessel normalization was assessed before and after induction phase using immunofluorescence and perfusion CT. This trial is registered with ClinicalTrials.gov (NCT03985046). Findings: Seventy-five patients with esophageal cancer were enrolled in this study between October 2019 and April 2021. The median follow-up of surviving patients was 33.6 months (IQR 29.3–35.7). The 2-year local control rate was 81.7% (95% confidence interval, 72.7%–90.7%), which was much higher than that in concurrent chemoradiation only (71.3%) in previous studies. Vascular normalization and hypoxia alleviation were observed in both biopsy specimens and perfusion CT. Interpretation: The addition of induction immunotherapy to standard concurrent chemoradiotherapy could improve radiosensitivity for locally advanced esophageal cancer as non-surgical treatment. New treatment combination led to higher local control rate through promoting vascular normalization and alleviating hypoxia. Our findings suggest that induction immunotherapy followed by concurrent chemoradiotherapy could be a potential option in future treatment. Funding: National Natural Science Foundation of China and Shanghai Rising-Star Program.
- Published
- 2024
- Full Text
- View/download PDF
5. Favorable prognosis of breast cancer brain metastases patients with limited intracranial and extracranial metastatic lesions
- Author
-
Wei Shi, Yang Li, Hua Sun, Li Zhang, Jin Meng, Xiaofang Wang, Xingxing Chen, Xiaomeng Zhang, Xin Mei, Jinli Ma, Miao Mo, Changming Zhou, Fei Liang, Zhimin Shao, Zhen Zhang, Xiaomao Guo, Xiaoli Yu, and Zhaozhi Yang
- Subjects
Brain metastases ,Breast cancer ,Oligometastases ,Systemic therapy ,Salvage local therapy ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Breast cancer brain metastases (BCBM) are highly heterogenous with widely differing survival. The prognosis of the oligometastatic breast cancer (BC) patients with brain metastases (BM) has not been well studied. We aimed to investigate the prognosis of BCBM patients with limited intracranial and extracranial metastatic lesions. Methods Four hundred and forty-five BCBM patients treated between 1st January 2008 and 31st December 2018 at our institute were included. Clinical characteristics and treatment information were obtained from patient’s medical records. The updated breast Graded Prognostic Assessment (Breast GPA) was calculated. Results The median OS after diagnosis of BM were 15.9 months. Median OS for patients with GPA 0–1.0, 1.5–2, 2.5–3 and 3.5–4 were 6.9, 14.2, 21.8, 42.6 months respectively. The total number of intracranial and extracranial metastatic lesions, in addition to the Breast GPA, salvage local therapy and systemic therapy (anti-HER2 therapy, chemotherapy and endocrine therapy) were demonstrated to be associated with prognosis. One hundred and thirteen patients (25.4%) had 1–5 total metastatic lesions at BM diagnosis. Patients with 1–5 total metastatic lesions had a significantly longer median OS of 24.3 months compared to those with greater than 5 total metastatic lesions with a median OS of 12.2 months (P
- Published
- 2023
- Full Text
- View/download PDF
6. Contralateral axillary lymph node metastasis in breast cancer: An oligometastatic-like disease
- Author
-
Qian Zhao, Fan Yang, Huai-liang Wu, Miao Mo, Yun-xiao Ling, and Guang-yu Liu
- Subjects
Breast cancer ,Contralateral axillary lymph node metastasis ,Oligometastasis ,Locoregional recurrence ,Prognosis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background: Contralateral axillary lymph node metastasis (CAM) is rare. It remains controversial whether CAM should be regarded as a regional or distant metastatic disease. Our study aims to investigate the accurate clinical orientation and management of CAM. Methods: Two hundred and ninety-nine female patients diagnosed with breast cancer from 2000 to 2014 and confirmed to develop CAM, oligometastasis (OM) or locoregional recurrence (LRR) at Fudan University Shanghai Cancer Center (FUSCC) were included in this study. Baseline information and survival outcomes were analyzed and compared among the three groups. Results: Patients with CAM exhibited similar overall survival (OS) and progression-free survival (PFS) to those with OM, but worse than those with LRR (HR: 0.47 [95 % CI: 0.27–0.85], p = 0.0097; HR:0.39 [95 % CI: 0.24–0.63], p
- Published
- 2023
- Full Text
- View/download PDF
7. Epidemiological landscape of esophageal cancer in Asia: Results from GLOBOCAN 2020
- Author
-
Hongcheng Zhu, Zezhou Wang, Bingbin Deng, Miao Mo, Honggang Wang, Ke Chen, Haoxuan Wu, Ting Ye, Boyan Wang, Dashan Ai, Shennan Hao, Ihsuan Tseng, and Kuaile Zhao
- Subjects
Asia ,epidemiology ,esophageal cancer ,gastrointestinal cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Esophageal cancer (EC) is a global health problem. Asia represents a huge burden of EC globally, and incidence and mortality vary considerably across different Asian regions. Methods Data on incidence, mortality, and preference were extracted from GLOBOCAN 2020. Age‐standardized incidence and mortality rates were calculated overall by sex, age, country, region, and continent. The predicted burden of incidence and mortality in 2040 was calculated based on global demographic projections. Results It was estimated there were 481 552 new cases of and 434 363 deaths from EC in Asia in 2020, accounting for 79.7% and 79.8% of world EC cases and deaths, respectively. EC incidence and mortality in Asia ranked the highest among all continents. Eastern Asia represents the highest age‐standardized world incidence rate (ASWIR) of 12.3 per 100 000 for all Asian regions. Western Asia represents the lowest ASWIR of 1.7 per 100 000, accounting for 0.7% of the globe. There exist obvious differences in epidemiological features in Asian countries, including incidence, mortality, prevalence, and mortality incidence ratio. There is forecast to be up to 781 000 new cases of EC in Asia by 2040, with increasing rates of 63% for incidence and 72% for mortality from 2020. Conclusions Asia has an increasing number of EC cases and deaths. Strategies for targeting in high‐incidence areas, the elderly, and survival should be prioritized to reduce the global EC burden, especially in low‐ and middle‐income countries in Asia.
- Published
- 2023
- Full Text
- View/download PDF
8. S100A5 Attenuates Efficiency of Anti‐PD‐L1/PD‐1 Immunotherapy by Inhibiting CD8+ T Cell‐Mediated Anti‐Cancer Immunity in Bladder Carcinoma
- Author
-
Huihuang Li, Jinbo Chen, Zhenghao Li, Minfeng Chen, Zhenyu Ou, Miao Mo, Ruizhe Wang, Shiyu Tong, Peihua Liu, Zhiyong Cai, Chunyu Zhang, Zhi Liu, Dingshan Deng, Jinhui Liu, Chunliang Cheng, Jiao Hu, and Xiongbing Zu
- Subjects
bladder carcinoma ,effector immune cells ,immunotherapy ,S100 family ,tumor microenvironment ,Science - Abstract
Abstract Although immune checkpoint blockade (ICB) therapies have been approved for bladder cancer (BLCA), only a minority of patients respond to these therapies, and there is an urgent need to explore combined therapies. Systematic multi‐omics analysis identified S100A5 as a novel immunosuppressive target for BLCA. The expression of S100A5 in malignant cells inhibited CD8+ T cell recruitment by decreasing pro‐inflammatory chemokine secretion. Furthermore, S100A5 attenuated effector T cell killing of cancer cells by inhibiting CD8+ T cell proliferation and cytotoxicity. In addition, S100A5 acted as an oncogene, thereby promoting tumor proliferation and invasion. Targeting S100A5 synergized with the efficacy of anti‐PD‐1 treatment by enhancing infiltration and cytotoxicity of CD8+ T cells in vivo. Clinically, there was a spatially exclusive relationship between S100A5+ tumor cells and CD8+ T cells in tissue microarrays. Moreover, S100A5 negatively correlated with immunotherapy efficacy in our real‐world and several public immunotherapy cohorts. In summary, S100A5 shapes a non‐inflamed tumor microenvironment in BLCA by inhibiting the secretion of pro‐inflammatory chemokines and the recruitment and cytotoxicity of CD8+ T cells. Targeting S100A5 converts cold tumors into hot tumors, thus enhancing the efficacy of ICB therapy in BLCA.
- Published
- 2023
- Full Text
- View/download PDF
9. WDHD1 is over‐expressed in nasopharyngeal carcinoma and may control the expression of ITGAV
- Author
-
Ji‐Yun Wu, Yi‐Tong Niu, Su‐Ning Huang, Yu‐Min Tan, Zhen‐Dong Yang, Ye‐Ying Fang, Li Jiang, Ting‐Ting Zhang, Xiao‐Fen Zeng, Yun‐Xi Peng, Miao Mo, Cai‐Xing Lin, and Zhu‐Xin Wei
- Subjects
bioinformatics ,cell cycle ,immunohistochemistry ,nasopharyngeal carcinoma ,WD repeat and HMG‐box DNA binding protein 1 ,Biology (General) ,QH301-705.5 - Abstract
Nasopharyngeal carcinoma (NPC) is a highly metastatic and invasive malignant tumor that originates in the nasopharynx. The DNA‐binding protein WD repeat and HMG‐box DNA‐binding protein 1 (WDHD1) are highly expressed in a variety of tumours, but its expression and mechanism of action in NPC have not been reported to date. To investigate the involvement of WDHD1 in NPC, we first mined databases for the gene expression profile of NPC. Immunohistochemistry (IHC) was performed on 338 cases of NPC and 112 non‐NPC samples to verify the results. We report that the expression of WDHD1 is significantly elevated in NPC. ChIP‐seq was used to show that integrin alpha V (ITGAV) and WDHD1 exhibit a significant binding peak in the promoter region of the ITGAV gene. The expression levels of ITGAV and WDHD1 exhibit a significant positive correlation, and IHC was performed to show that ITGAV is highly expressed in NPC. Expression of ITGAV increased after overexpression of WDHD1, suggesting that ITGAV may be a potential target gene of WDHD1. Pathway analysis showed that both genes were closely related to the cell cycle, and flow cytometry was used to further confirm that decreased expression of WDHD1 significantly increased the number of apoptotic cells. In conclusion, our results suggest that expression of WDHD1 is increased in NPC and is likely to be associated with the NPC cell cycle; thus, we propose that WDHD1 may have the potential as a target gene for primary screening and treatment of NPC.
- Published
- 2023
- Full Text
- View/download PDF
10. Treatment and survival outcomes in older women with primary breast cancer: A retrospective propensity score-matched analysis
- Author
-
Yuting Sang, Benlong Yang, Miao Mo, Shiyang Liu, Xujie Zhou, Jiajian Chen, Shuang Hao, Xiaoyan Huang, Guangyu Liu, Zhimin Shao, and Jiong Wu
- Subjects
Breast cancer ,Older women ,Treatment strategy ,Clinicopathological features ,Survival outcomes ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Purpose: Changes in biological features and functional status make management decisions in older women with primary breast cancer complicated. We aimed to provide an overview of the clinicopathological characteristics and survival outcomes of older breast cancer patients based on the current treatment strategies. Methods: Female patients diagnosed with primary invasive breast cancer at Fudan University Shanghai Cancer Centre from 2008 to 2016 were included. Patients were divided into a younger group (
- Published
- 2022
- Full Text
- View/download PDF
11. Predictors of cancer screening behavior of the working population in China based on the information-motivation-behavioral skills model
- Author
-
Zezhou Wang, Changming Zhou, Li Zhang, Jie Shen, Miao Mo, Yulian He, and Ying Zheng
- Subjects
information-motivation-behavioral skills model (IMB) ,cancer screening ,behavior change ,working population ,behavioral skills ,China ,Public aspects of medicine ,RA1-1270 - Abstract
BackgroundThe cancer screening rate in the working population is very low in China. Information-motivation-behavioral skills (IMB) model has been applied to elucidate screening behavior for various chronic diseases but has not been investigated in analyzing cancer screening behavior. This study aimed to examine factors influencing cancer screening behavior and their linkages based on the IMB model.MethodsA cross-sectional study was conducted in Shanghai, China from August to October 2021. Data were obtained through an anonymous questionnaire. Predictive relationships between variables in the IMB model and cancer screening behavior were evaluated. Structural equation modeling (SEM) was constructed to demonstrate the utility of the IMB model.ResultsAmong the 556 participants included in the analysis, 34.4% of participants had ever done a cancer screening. The construct validation analysis supported that the measure items included were acceptable. SEM found that knowledge of cancer warning signs and symptoms (β = 0.563, p
- Published
- 2023
- Full Text
- View/download PDF
12. Dose escalation based on 18F-FDG PET/CT response in definitive chemoradiotherapy of locally advanced esophageal squamous cell carcinoma: a phase III, open-label, randomized, controlled trial (ESO-Shanghai 12)
- Author
-
Hongcheng Zhu, Qiufang Liu, Hao Xu, Miao Mo, Zezhou Wang, Kui Lu, Jialiang Zhou, Junqiang Chen, Xiangpeng Zheng, Jinjun Ye, Xiaolin Ge, Honglei Luo, Qi Liu, Jiaying Deng, Dashan Ai, Shengnan Hao, Junhua Zhang, I Hsuan Tseng, Shaoli Song, Yun Chen, and Kuaile Zhao
- Subjects
Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Introduction Definitive chemoradiotherapy has established the standard non-surgical treatment for locally advanced esophageal cancer. The standard dose of 50–50.4 Gy has been established decades ago and been confirmed in modern trials. The theorical advantage of better local control and technical advances for less toxicity have encouraged clinicians for dose escalation investigation. 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) have the potential to tailor therapy for esophageal patients not showing response to CRT and pioneers the PET-based dose escalation. Methods and analysis The ESO-Shanghai 12 trial is a prospective multicenter randomized phase 3 study in which patients are randomized to either 61.2 Gy or 50.4 Gy of radiation dose by PET response. Both groups undergo concurrent chemoradiotherapy with paclitaxel/cisplatin regimen for 2 cycles followed by consolidation chemotherapy for 2 cycles. Patients with histologically confirmed ESCC [T1N1-3M0, T2-4NxM0, TxNxM1 (Supraclavicular lymph node metastasis only), (AJCC Cancer Staging Manual, 8th Edition)] and without any prior treatment of chemotherapy, radiotherapy or surgery against esophageal cancer will be eligible. The primary endpoints included overall survival in PET/CT non-responders (SUVmax > 4.0) and overall survival in total population. Patients will be stratified by standardized uptake volume, gross tumor volume and tumor location. The enrollment could be ended, when the number of PET/CT non-responder reached 132 and the total population reached 646 for randomization. Ethics and dissemination This trial has been approved by the Fudan University Shanghai Cancer Center Institutional Review Board. Trial results will be disseminated via peer reviewed scientific journals and conference presentations. Trial registration The trial was initiated in 2018 and is currently recruiting patients. Trial registration number NCT03790553.
- Published
- 2022
- Full Text
- View/download PDF
13. A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study
- Author
-
Menglong Zhou, Wang Yang, Yan Xuan, Wei Zou, Yaqi Wang, Zhiyuan Zhang, Jing Zhang, Miao Mo, Changming Zhou, Yuan Liu, Wenming Zhang, Zhaozhen Zhang, Yiping He, Weiwei Weng, Cong Tan, Lei Wang, Dan Huang, Weiqi Sheng, Huanhuan Li, Hui Zhu, Yan Wang, Lijun Shen, Hui Zhang, Juefeng Wan, Guichao Li, Hua Huang, Yanong Wang, Zhen Zhang, Xiaowen Liu, and Fan Xia
- Subjects
Locally advanced gastric cancer ,Gastroesophageal junction adenocarcinoma ,Preoperative chemoradiation ,Immunotherapy ,Gastrectomy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Perioperative chemotherapy (ChT) and preoperative chemoradiation (CRT) are both the standard treatments for locally advanced gastric cancer (LAGC). CRT can achieve a higher pathological complete regression (pCR) rate, but whether this higher pCR rate can be transformed into a long-term survival benefit remains inconclusive. Therefore, relevant studies are in progress. On the other hand, immunotherapy has been established for the first-line treatment of advanced gastric cancer (AGC) and has been widely explored in the perioperative setting. The combination of chemotherapy/radiotherapy and immunotherapy may have a synergistic effect, which will lead to a better antitumor effect. The preliminary reports of ongoing studies show promising results, including a further improved pCR rate. However, the preferred treatment combination for LAGC is still not established. To solve this problem, we are carrying out this randomized phase II trial, which aims to evaluate the efficacy and safety of perioperative chemotherapy plus the use of PD-1 antibody with or without preoperative chemoradiation for LAGC. Methods Eligible patients with LAGC or gastroesophageal junction (GEJ) adenocarcinoma were randomized to receive perioperative ChT, PD-1 antibody, surgery with (Arm A) or without preoperative CRT (Arm B), and PD-1 antibody maintenance until one year after surgery. The primary endpoint of this study is that the pCR rate of Arm A will be significantly higher than that of Arm B. The secondary endpoints include the pathological partial regression (pPR) rate, R0 resection rate, objective response rate (ORR), event-free survival (EFS), overall survival (OS), safety and surgical complications. Moreover, several explorative endpoints will be evaluated to find and validate the predictive biomarkers of immunotherapy. Discussion The results of the NeoRacing study will provide important information concerning the application of PD-1 antibody in LAGC patients during the perioperative setting. Meanwhile, the two treatment protocols will be compared in terms of efficacy and safety. Trial registration ClinicalTrials.gov , NCT05161572 . Registered 17 December 2021 - Retrospectively registered.
- Published
- 2022
- Full Text
- View/download PDF
14. Breast cancer screening and early diagnosis in Chinese women
- Author
-
Rui Ding, Yi Xiao, Miao Mo, Ying Zheng, Yi-Zhou Jiang, and Zhi-Ming Shao
- Subjects
breast cancer ,screening ,chinese ,imaging screening ,genetic test ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Breast cancer is the most common malignant tumor in Chinese women, and its incidence is increasing. Regular screening is an effective method for early tumor detection and improving patient prognosis. In this review, we analyze the epidemiological changes and risk factors associated with breast cancer in China and describe the establishment of a screening strategy suitable for Chinese women. Chinese patients with breast cancer tend to be younger than Western patients and to have denser breasts. Therefore, the age of initial screening in Chinese women should be earlier, and the importance of screening with a combination of ultrasound and mammography is stressed. Moreover, Chinese patients with breast cancers have several ancestry-specific genetic features, and aiding in the determination of genetic screening strategies for identifying high-risk populations. On the basis of current studies, we summarize the development of risk-stratified breast cancer screening guidelines for Chinese women and describe the significant improvement in the prognosis of patients with breast cancer in China.
- Published
- 2022
- Full Text
- View/download PDF
15. Time‐varying effect of sex on prognosis of lung adenocarcinoma surgical patients in China
- Author
-
Zezhou Wang, Miao Mo, Changming Zhou, Xiaoshuang Feng, Jie Shen, Ting Ye, Yang Zhang, Hong Hu, Haiquan Chen, and Ying Zheng
- Subjects
adenocarcinoma ,inverse probability of treatment weighting ,prognosis ,sex ,time‐dependent effect ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Little is known about the prognostic advantage of sex for pulmonary adenocarcinoma among Chinese patients. In this study, we aimed to investigate the true sex differences in prognosis by adjusting for confounders and to explore whether the differences were time‐varying. Methods We identified 4438 lung adenocarcinoma patients who underwent surgery at a regional Cancer Center of China from 2008 to 2016, retrospectively. Sex, age group, smoking history, year of diagnosis and pathological stage were collected. Time‐dependent Cox regression models with inverse probability of treatment weighting (IPTW) based on propensity score were used to assess the effect of sex and account for confounders. Landmark analyses were conducted to assess survival before, and after, five years. Results Of these patients, 1761 (39.7%) were men and 2677 (60.3%) were women. Median follow‐up time was 52.6 months. After IPTW adjustment, women were found to have significantly better survival than men varying with time in both crude and IPTW models (hazard ratio [HR] [t] = 0.453*1.015t, where t is the length of time from treatment and its unit is month, p
- Published
- 2021
- Full Text
- View/download PDF
16. The Application and Comparison of Machine Learning Models for the Prediction of Breast Cancer Prognosis: Retrospective Cohort Study
- Author
-
Jialong Xiao, Miao Mo, Zezhou Wang, Changming Zhou, Jie Shen, Jing Yuan, Yulian He, and Ying Zheng
- Subjects
Computer applications to medicine. Medical informatics ,R858-859.7 - Abstract
BackgroundOver the recent years, machine learning methods have been increasingly explored in cancer prognosis because of the appearance of improved machine learning algorithms. These algorithms can use censored data for modeling, such as support vector machines for survival analysis and random survival forest (RSF). However, it is still debated whether traditional (Cox proportional hazard regression) or machine learning-based prognostic models have better predictive performance. ObjectiveThis study aimed to compare the performance of breast cancer prognostic prediction models based on machine learning and Cox regression. MethodsThis retrospective cohort study included all patients diagnosed with breast cancer and subsequently hospitalized in Fudan University Shanghai Cancer Center between January 1, 2008, and December 31, 2016. After all exclusions, a total of 22,176 cases with 21 features were eligible for model development. The data set was randomly split into a training set (15,523 cases, 70%) and a test set (6653 cases, 30%) for developing 4 models and predicting the overall survival of patients diagnosed with breast cancer. The discriminative ability of models was evaluated by the concordance index (C-index), the time-dependent area under the curve, and D-index; the calibration ability of models was evaluated by the Brier score. ResultsThe RSF model revealed the best discriminative performance among the 4 models with 3-year, 5-year, and 10-year time-dependent area under the curve of 0.857, 0.838, and 0.781, a D-index of 7.643 (95% CI 6.542, 8.930) and a C-index of 0.827 (95% CI 0.809, 0.845). The statistical difference of the C-index was tested, and the RSF model significantly outperformed the Cox-EN (elastic net) model (C-index 0.816, 95% CI 0.796, 0.836; P=.01), the Cox model (C-index 0.814, 95% CI 0.794, 0.835; P=.003), and the support vector machine model (C-index 0.812, 95% CI 0.793, 0.832; P
- Published
- 2022
- Full Text
- View/download PDF
17. Tumor microenvironment responsive drug delivery systems
- Author
-
Qunye He, Jun Chen, Jianhua Yan, Shundong Cai, Hongjie Xiong, Yanfei Liu, Dongming Peng, Miao Mo, and Zhenbao Liu
- Subjects
Cancer therapy ,Stimuli responsive ,Dynamic targeting ,Drug delivery system ,Controlled release ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Conventional tumor-targeted drug delivery systems (DDSs) face challenges, such as unsatisfied systemic circulation, low targeting efficiency, poor tumoral penetration, and uncontrolled drug release. Recently, tumor cellular molecules-triggered DDSs have aroused great interests in addressing such dilemmas. With the introduction of several additional functionalities, the properties of these smart DDSs including size, surface charge and ligand exposure can response to different tumor microenvironments for a more efficient tumor targeting, and eventually achieve desired drug release for an optimized therapeutic efficiency. This review highlights the recent research progresses on smart tumor environment responsive drug delivery systems for targeted drug delivery. Dynamic targeting strategies and functional moieties sensitive to a variety of tumor cellular stimuli, including pH, glutathione, adenosine-triphosphate, reactive oxygen species, enzyme and inflammatory factors are summarized. Special emphasis of this review is placed on their responsive mechanisms, drug loading models, drawbacks and merits. Several typical multi-stimuli responsive DDSs are listed. And the main challenges and potential future development are discussed.
- Published
- 2020
- Full Text
- View/download PDF
18. Prostate‐specific antigen modulates the osteogenic differentiation of MSCs via the cadherin 11‐Akt axis
- Author
-
Longxiang Wu, Shiqi Xiang, Xiheng Hu, Miao Mo, Cheng Zhao, Yi Cai, Shiyu Tong, Huichuan Jiang, Linxiao Chen, Zhi Wang, Wei Xiong, and Zhenyu Ou
- Subjects
prostate‐specific antigen ,mesenchymal stem cell ,osteogenesis ,prostate cancer ,Medicine (General) ,R5-920 - Abstract
Abstract Background A high prevalence of osteoblastic bone metastases is characteristic of prostate cancer. Prostate‐specific antigen (PSA) is a serine protease uniquely produced by prostate cancer cells and is an important serological marker for prostate cancer. However, whether PSA modulates the osteogenic process remains largely unknown. In this study, we explored the effect of PSA on modulating the osteoblastic differentiation of mesenchymal stem cells (MSCs). In this study, we used flow cytometry, CCK‐8 assay, Alizarin red S (ARS) staining and quantification, alkaline phosphatase (ALP) activity and staining, Western blotting, and quantitative real‐time PCR (qRT‐PCR) to explore the effect of PSA on osteogenic differentiation of MSCs. Results We first demonstrated that although PSA did not affect the proliferation, morphology, or phenotype of MSCs, it significantly promoted the osteogenic differentiation of MSCs in a concentration‐dependent manner. Furthermore, we demonstrated that PSA promoted the osteogenic differentiation of MSCs by elevating the expression of Cadherin 11 in MSCs and, thus, activating the Akt signaling pathway. Conclusions In conclusion, we demonstrated that PSA could promote the osteogenesis of MSCs through Akt signaling pathway activation by elevating the expression of cadherin‐11 in MSCs. These findings imply a possible role of PSA in osteoblastic bone metastases in prostate cancer.
- Published
- 2020
- Full Text
- View/download PDF
19. Risk Factors Associated With Early-Onset Colorectal Neoplasm in Chinese Youth: A Prospective Population-Based Study
- Author
-
Jie Shen, Yiling Wu, Miao Mo, Xiaoshuang Feng, Changming Zhou, Zezhou Wang, Guoxiang Cai, and Ying Zheng
- Subjects
risk factors ,prospective population-based study ,colorectal cancer ,early-onset ,screening ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Evidence of the risk factors associated with early-onset colorectal neoplasm from prospective population-based studies is limited. We enrolled 17,293 participants younger than 50 years from the Shanghai colorectal cancer (CRC) screening program cohort. Face-to-face interviews were performed by trained primary care physicians using a standardized questionnaire to collect the information on potential risk factors at baseline entry. Furthermore, 124 cases of early-onset colorectal neoplasm, including six CRC cases and 118 colorectal adenoma (CRA) cases, were detected between 2012 and 2016. Multivariable logistic regression models and restricted cubic spline (RCS) were used to evaluate the risk factors associated with early-onset colorectal neoplasm. We found that sex, body mass index (BMI), and family history of CRC were associated with the early onset of colorectal neoplasm. The RCS model showed a positive dose–response and linear association between BMI and risk of early-onset colorectal neoplasm among young participants (p-overall = 0.19, p-nonlinear = 0.97). The findings indicated that it was beneficial for normal people younger than 50 years to start opportunistic CRC screening. As for those at high risk, increased surveillance is strongly recommended. Further close follow-up is required for research on the underlying causes of early-onset CRC.
- Published
- 2021
- Full Text
- View/download PDF
20. Identifying a Ferroptosis-Related Gene Signature for Predicting Biochemical Recurrence of Prostate Cancer
- Author
-
Zhengtong Lv, Jianlong Wang, Xuan Wang, Miao Mo, Guyu Tang, Haozhe Xu, Jianye Wang, Yuan Li, and Ming Liu
- Subjects
prostate cancer ,TCGA ,MSKCC ,ferroptosis ,prognosis ,biochemical recurrence ,Biology (General) ,QH301-705.5 - Abstract
Ferroptosis induced by lipid peroxidation is closely related to cancer biology. Prostate cancer (PCa) is not only a malignant tumor but also a lipid metabolic disease. Previous studies have identified ferroptosis as an important pathophysiological pathway in PCa development and treatment, but its role in the prognosis of PCa is less well known. In this study, we constructed a nine-ferroptosis-related gene risk model that demonstrated strong prognostic and therapeutic predictive power. The higher risk score calculated by the model was significantly associated with a higher ferroptosis potential index, higher Ki67 expression, higher immune infiltration, higher probability of biochemical recurrence, worse clinicopathological characteristics, and worse response to chemotherapy and antiandrogen therapy in PCa. The mechanisms identified by the gene set enrichment analysis suggested that this signature can accurately distinguish high- and low-risk populations, which is possibly closely related to variations in steroid hormone secretion, regulation of endocrine processes, positive regulation of humoral immune response, and androgen response. Results of this study were confirmed in two independent PCa cohorts, namely, The Cancer Genome Atlas cohort and the MSK-IMPACT Clinical Sequencing Cohort, which contributed to the body of scientific evidence for the prediction of biochemical recurrence in patients with PCa. In addition, as the main components of this signature, the effects of the AIFM2 and NFS1 genes on ferroptosis were evaluated and verified by in vivo and in vitro experiments, respectively. The above findings provided new insights and presented potential clinical applications of ferroptosis in PCa.
- Published
- 2021
- Full Text
- View/download PDF
21. Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial
- Author
-
Ke-Da Yu, Xi-Yu Liu, Li Chen, Miao Mo, Jiong Wu, Guang-Yu Liu, Gen-Hong Di, Claire Verschraegen, Daniel G. Stover, Zhi-Gang Zhuang, François Bertucci, Armando Orlandi, Jie Wang, Giuseppe Lippi, Ke-Jin Wu, Mohammed A. Osman, Lei Fan, and Zhi-Ming Shao
- Subjects
Public aspects of medicine ,RA1-1270 - Abstract
Background: De-escalating anthracycline is gaining popularity for breast cancer patients. We aim to evaluate the non-inferiority of an anthracycline-free or short-term regimen to the standard anthracycline-based regimen for operable patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Methods: It is a prospective, open-label, phase 3, randomized non-inferiority trial from June 1, 2010 to June 1, 2017. Follow-up had been kept until July 2019. This trial was conducted at Fudan University Shanghai Cancer Center. Patients with pT1–3N+ or pT2–3N0 but high-risk (grade II/III, lymphovascular invasion, ≤35 years of age or hormone-receptor negative) HER2-negative operable breast cancer were eligible and stratified by age, pathological tumour stage, pathological node status and hormone-receptor status. Patients were randomized to 6 cycles of docetaxel and cyclophosphamide (TC, n = 524), 3 cycles of cyclophosphamide/epirubicin/fluorouracil followed by 3 cycles of docetaxel (CEF-T, n = 523) or epirubicin and cyclophosphamide for 4 cycles followed by paclitaxel for 12 weeks (EC-P, n = 524) as the intention-to-treat population. Of these patients, 94% completed allocated therapy. Difference in disease-free survival (DFS) compared to EC-P. The prespecified non-inferiority margin was 4.5%, corresponding to the hazard ratio (HR) of 1.44 (one-sided α = 0.05), with an assumed 5-year DFS of 89% for EC-P. Findings: Included in the intention-to-treat population were 1571 patients (median [IQR] age, 50 [45–57] years; 92% estrogen receptor [ER]-positive; 59% pN+). Through a median follow-up of 5.5 years, HR for TC versus EC-P was 1.05 (5-year DFS: 85.0% vs. 85.9%; 90% confidence interval [CI]: 0.79–1.39, non-inferior P = 0.048) and for CEF-T versus EC-P, 0.99 (5-year DFS: 85.1% vs. 85.9%; 90% CI: 0.75–1.30, non-inferior P = 0.045). Grade 3 or 4 adverse events for TC included rash (3.9%) and peripheral neuropathy (2.8%) and for CEF-T and EC-P diarrhea and nausea/vomiting were predominant. Results of per-protocol analyses were similar. Interpretation: Both TC and CEF-T are non-inferior adjuvant regimen to EC-P mainly in patients with ER+HER2- breast cancer. TC is a safe regimen that avoids anthracycline-related side effects. Funding: This work was supported by grants from the National Natural Science Foundation of China (Grants 81672600, 81722032, 82072916, and 91959207), the 2018 Shanghai Youth Excellent Academic Leader, the Fudan ZHUOSHI Project, the Municipal Project for Developing Emerging and Frontier Technology in Shanghai Hospitals (grant SHDC12010116), the Cooperation Project of Conquering Major Diseases in the Shanghai Municipality Health System (grant 2013ZYJB0302), the Innovation Team of the Ministry of Education (grant IRT1223), and the Shanghai Key Laboratory of Breast Cancer (grant 12DZ2260100) and the National Cancer Institute (grant P30 CA16058).
- Published
- 2021
- Full Text
- View/download PDF
22. Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
- Author
-
Yifan Xie, Siyu Wu, Ying Zhang, Jianwei Li, Miao Mo, Zhimin Shao, and Guangyu Liu
- Subjects
breast cancer ,human epithelial growth factor receptor 2 ,neoadjuvant chemotherapy ,pathologic complete response ,event free survival ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
BackgroundTaxane, carboplatin and trastuzumab (TCH) is an effective neoadjuvant regimen for human epidermal growth factor receptor 2 (HER2)-positive breast cancer with high pathologic complete response (pCR) rate. The KATHERINE trial changes the outlook for high-risk HER2-positive breast cancer, which suggests that escalation treatment for patients with residual disease after neoadjuvant anti-HER2 therapy may improve survival. The major objective of this study was to investigate the fewest cycles of neoadjuvant TCH therapy needed to screen out non-pCR patients.MethodsThis retrospective study included patients with HER2-positive breast cancer who received either four or six cycles of TCH preoperatively at Fudan University Shanghai Cancer Center between 2008 and 2019. The pCR status was evaluated, and relevant factors associated with pCR were identified using univariate and multivariable analyses. The pathological results of core needle biopsy (CNB) in the breast tumor after two cycles of neoadjuvant chemotherapy were also collected. Kaplan-Meier curve was used to estimate the event-free survival (EFS).ResultsOf 758 eligible patients, 303 were included and analyzed in the four-cycle group and 455 in the six-cycle group. There was no significant difference between the two groups in terms of the pCR rate (46.5% [95% CI 40.9% - 52.2%] in the four-cycle group and 49.9% [95% CI 45.3% - 54.5%] in the six-cycle group, p = 0.365) or the four-year EFS (90.8% in four-cycle group and 93.8% in six-cycle group; p = 0.264). Multivariable analysis indicated that a negative hormone receptor status and the weekly paclitaxel were independent factors for predicting pCR. After adjusting for factors in the multivariable analysis, there was still no significant difference between four and six cycles of neoadjuvant TCH (OR = 1.252, 95% CI 0.904 - 1.733, p = 0.176). Furthermore, 17.9% patients with invasive carcinoma on CNB after two cycles of TCH ultimately achieved pCR in the breast after the completion of neoadjuvant treatment.ConclusionFour cycles of taxane/carboplatin-based neoadjuvant anti-HER2 therapy may be applied as an optimal treatment duration for screening high-risk HER2-positive breast cancer patients for escalation treatment. Further prospective study is warranted.
- Published
- 2021
- Full Text
- View/download PDF
23. Identification of a Novel Glycolysis-Related Gene Signature Correlates With the Prognosis and Therapeutic Responses in Patients With Clear Cell Renal Cell Carcinoma
- Author
-
Zhengtong Lv, Lin Qi, Xiheng Hu, Miao Mo, Huichuan Jiang, and Yuan Li
- Subjects
clear cell renal cell carcinoma ,TCGA ,glycolysis ,prognosis ,gene set enrichment analysis (GSEA) ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
BackgroundAccumulating evidences indicate significant alterations in the aerobic glycolysis in clear cell renal cell carcinoma (ccRCC). We aim to develop and validate a glycolysis-related genes signature for predicting the clinical outcomes of patients with ccRCC.MethodsmRNA expression profiling of ccRCC was obtained from The Cancer Genome Atlas database. Univariate Cox regression analysis and lasso Cox regression model were performed to identify and construct the prognostic gene signature. The protein expression levels of the core genes were obtained from the Human Protein Atlas database. We used four external independent data sets to verify the predictive power of the model for prognosis, tyrosine kinase inhibitor (TKI) therapy, and immunotherapy responses, respectively. Finally, we explored the potential mechanism of this signature through gene set enrichment analysis (GSEA).ResultsThrough the GSEA, glycolysis-related gene sets were significantly different between ccRCC tissues and normal tissues. Next, we identified and constructed a seven-mRNA signature (GALM, TGFA, RBCK1, CD44, HK3, KIF20A, and IDUA), which was significantly correlated with worse survival outcome and was an independent prognostic indicator for ccRCC patients. Furthermore, the expression levels of hub genes were validated based on the Human Protein Atlas databases. More importantly, the model can predict patients’ response to TKI therapy and immunotherapy. These findings were successfully validated in the external independent ccRCC cohorts. The mechanism exploration showed that the model may influence the prognosis by influencing tumor proliferation, base mismatch repair system and immune status of patients.ConclusionsOur study has built up a robust glycolysis-based molecular signature that predicts the prognosis and TKI therapy and immunotherapy responses of patients with ccRCC with high accuracy, which might provide important guidance for clinical assessment. Also, clinical investigations in large ccRCC cohorts are greatly needed to validate our findings.
- Published
- 2021
- Full Text
- View/download PDF
24. Zic Family Member 2 (ZIC2): a Potential Diagnostic and Prognostic Biomarker for Pan-Cancer
- Author
-
Zhengtong Lv, Lin Qi, Xiheng Hu, Miao Mo, Huichuan Jiang, Benyi Fan, and Yuan Li
- Subjects
pan-cancer ,Zic2 ,prognosis ,TCGA ,biomarker ,Biology (General) ,QH301-705.5 - Abstract
Background: As a transcription factor, Zinc finger protein ZIC2 can interact with various DNAs and proteins. Current studies have shown that ZIC2 plays an oncogene role in various cancers. In this study, we systematically characterize the prevalence and predictive value of ZIC2 expression across multiple cancer types.Methods: We mined several public databases, including Oncomine, the Cancer Genome Atlas (TCGA), cBioPortal, Kaplan-Meier Plotter and PrognoScan to evaluated the differentially expressed ZIC2 between tumor samples and normal control samples in pan-cancner, and then explored the association between ZIC2 expression and patient survival, prognosis and clinicopathologic stage. We also analyzed the relationship between tumor mutation burden (TMB), microsatellite instability (MSI), tumor microenvironment, tumor- and immune-related genes and ZIC2 expression. Finally, we explored the potential signaling pathway mechanism through gene set enrichment analysis (GSEA).Results: ZIC2 expression was higher in most cancer tissues compared with adjacent normal tissues. High ZIC2 expression was associated with worse prognosis and a higher clinicopathologic stage. ZIC2 expression was strongly associated with the TMB, MSI, tumor microenvironment and tumor- and immune-related genes. The GSEA revealed that multiple tumor- and immune-related pathways were differentially enriched in ZIC2 high or low expression phenotype.Conclusion: ZIC2 expression may be a potential prognostic molecular biomarker of poor survival in pan-cancer and may act as an oncogene with a strong effect in the processes of tumorigenesis and progression.
- Published
- 2021
- Full Text
- View/download PDF
25. A Short-Term Effect of Wearable Technology-Based Lifestyle Intervention on Body Composition in Stage I–III Postoperative Breast Cancer Survivors
- Author
-
Changming Zhou, Miao Mo, Zezhou Wang, Jie Shen, Jiajian Chen, Lichen Tang, Jiajia Qiu, Yiqun Ling, Huiping Ding, Qin Jiang, Hui Wang, Zhimin Shao, and Ying Zheng
- Subjects
breast cancer ,body weight ,body composition ,life-style intervention ,wearable technology ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background and AimA healthy body composition can improve the prognosis of breast cancer survivors. The study aimed to describe the body composition profile of breast cancer survivors and find out whether a short-term (3 months) wearable device-based lifestyle intervention had an effect on patients’ body weight and body composition.MethodsA before-and-after study was conducted on patients with stage I–III postoperative breast cancer, aged 18–70 years. Body composition was analyzed at baseline, and then patients went for a health education program. A wearable activity tracker and a goal of calorie consumption based on each individual’s weight were provided to each participant, and they were required to be equipped for 90 days. After 3 months, body composition was analyzed again.ResultsOf 113 patients who completed the study, 65.49% showed a normal body mass index (BMI) at baseline assessment, 71.68% had a body fat percentage of more than 30%, and 41.59% had less skeleton muscle mass. During the intervention, the daily step count was 8,851.28 ± 2,399.31, and 59.21% reached the set goal calorie consumption. After a 3-month intervention, the patients had a significant reduction in body weight, fat mass, BMI, body fat percentage, and visceral fat area, but not in protein mass and skeleton muscle mass. Patients of different age, molecular classification, and therapy benefited from the intervention.ConclusionWearable technology with body composition analysis and health education for breast cancer survivors may help reduce weight and improve body composition even in a short time.Clinical Trial Registrationhttp://www.chictr.org.cn/showproj.aspx?proj=40672, identifier ChiCTR1900024258.
- Published
- 2020
- Full Text
- View/download PDF
26. Dual Inhibition of Pirarubicin-Induced AKT and ERK Activations by Phenformin Sensitively Suppresses Bladder Cancer Growth
- Author
-
Mei Peng, Jun Deng, Sichun Zhou, Di Xiao, Jiahui Long, Nan Zhang, Caimei He, Miao Mo, and Xiaoping Yang
- Subjects
Akt ,ERK ,pirarubicin ,phenformin ,bladder cancer ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Activations of Akt or ERK pathway induced by clinical drugs promote therapeutic failure due to decrease of drug response, and no available strategies have been developed to solve these problems. In this study, we found that pirarubicin (THP), one important chemotherapeutic drug for treating bladder cancer intravesically, dramatically elevated phosphorylations of both Akt and Erk1/2 in addition to inducing DNA damage. MK2206 or AZD6244, representative Akt and Erk1/2 inhibitors, respectively, profoundly sensitized bladder cancer cells to THP treatment. Interestingly, we found that inhibition of a single arm of either Akt or Erk1/2 pathway would induce the increase of another arm, indicating the existence of the crosstalk between these two pathways. Thus, simultaneous suppression of both signals may be needed for increasing the sensitivity of THP. On the other hand, we revealed that phenformin efficiently inhibited both Akt and Erk1/2 phosphorylation in a dose-dependent manner. Furthermore, we demonstrated that phenformin, mimicking dual inhibitors, plays dramatically synergistic action with THP both in vitro and in vivo. Our findings suggest that combination therapy of THP with dual inhibitors may constitute a successful strategy for improving chemotherapy response.
- Published
- 2019
- Full Text
- View/download PDF
27. A prospective study of breast anthropomorphic measurements, volume and ptosis in 605 Asian patients with breast cancer or benign breast disease.
- Author
-
Nai-Si Huang, Chen-Lian Quan, Miao Mo, Jia-Jian Chen, Ben-Long Yang, Xiao-Yan Huang, and Jiong Wu
- Subjects
Medicine ,Science - Abstract
OBJECTIVES:The current study aims to summarize breast anthropomorphic measurement features in Chinese patients with breast diseases and to investigate their potential correlations with demographic factors. MATERIALS AND METHODS:Fifteen breast anthropomorphic parameters of 605 Chinese female patients were collected prospectively. Breast ptosis status was scaled by two methods and breast volume was calculated according to a modified formula of BREAST-V. RESULTS:Among 1210 breasts, the average breast volume was 340.0±109.1 ml (91.8-919.2 ml). The distance from the nipple to the inframammary fold was 7.5±1.6 cm in the standing position. The width of the breast base was 14.3±1.4 cm (8.5-23.5 cm). The incidence of breast ptosis was 22.8% (274/1204), of which 37 (23.5%) and 79 (31.7%) women had severe ptosis assessed by different criteria. Increased height (OR[odds ratio] = 1.500, P
- Published
- 2017
- Full Text
- View/download PDF
28. CCL21/CCR7 enhances the proliferation, migration, and invasion of human bladder cancer T24 cells.
- Author
-
Miao Mo, Mi Zhou, Lu Wang, Lin Qi, Kehua Zhou, Long-Fei Liu, Zhi Chen, and Xiong-Bing Zu
- Subjects
Medicine ,Science - Abstract
To investigate the effects of CCL21/CCR7 on the proliferation, migration, and invasion of T24 cells and the possible associated mechanisms: expression of MMP-2 and MMP-9, and regulation of BCL-2 and BAX proteins.T24 cells received corresponding treatments including vehicle control, antibody (20 ng/mL CCR7 antibody and 50 ng/ml CCL21), and 50, 100, and 200 ng/ml CCL21. Proliferation was evaluated by MTT assay; cell migration and invasion were assayed using a transwell chamber. Cell apoptosis was induced by Adriamycin (ADM). The rate of cell apoptosis was examined by flow cytometry using annexin V-FITC/PI staining. Western-blot was used to analyze MMP-2 and MMP-9 and BCL-2 and BAX proteins.CCL21 promoted T24 cell proliferation in concentration-dependent manner with that 200 ng/mL induced the largest amount of proliferation. Significant differences of cell migration were found between CCL21treatment groups and the control group in both the migration and invasion studies (P < 0.001 for all). The expressions of MMP-2 and MMP-9 proteins were significantly increased after CCL21 treatment (p < 0.05 for all). Protein expression of Bcl-21 follows an ascending trend while the expression of Bax follows a descending trend as the concentration of CCL21 increases. No difference was found between the control group and antibody group for all assessments.CCL21/CCR7 promoted T24 cell proliferation and enhanced its migration and invasion via the increased expression of MMP-2 and MMP-9. CCL21/CCR7 had antiapoptotic activities on T24 cells via regulation of Bcl-2 and Bax proteins. CCL21/CCR7 may promote bladder cancer development and metastasis.
- Published
- 2015
- Full Text
- View/download PDF
29. ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy.
- Author
-
Jian-Wei Li, Miao Mo, Ke-da Yu, Can-Ming Chen, Zhen Hu, Yi-Feng Hou, Gen-Hong Di, Jiong Wu, Zhen-Zhou Shen, Zhi-Ming Shao, and Guang-Yu Liu
- Subjects
Medicine ,Science - Abstract
The study was to estimate the likelihood of axillary downstaging and to identify the factors predicting a pathologically node negative status after neoadjuvant chemotherapy (NAC) with or without trastuzumab in HER2-positive breast cancer.Patients with HER2-positive, stage IIa-IIIc breast cancer were enrolled. Axillary status was evaluated by palpation and fine needle aspiration (FNA) before NAC. All patients received 4-6 cycles of PCrb (paclitaxel 80 mg/m2 and carboplatin AUC = 2 d1, 8, and 15 of a 28-day cycle, or paclitaxel 175 mg/m2 and carboplatin AUC = 6 every-3-week) and were non-randomly administered trastuzumab (2 mg/kg weekly or 6 mg/kg every-3-week) or not. After NAC, each patient underwent standard axillary lymph node dissection and breast-conserving surgery or mastectomy. And some patients received sentinel lymph node biopsy (SLNB) before axillary dissection.Between November-2007 and June-2013, 255 patients were enrolled. Of them, 157 were confirmed as axillary node positive by FNA (group-A) and 98 as axillary node negative either by FNA or impalpable (group-B). After axillary dissection, the overall pathologically node negative rates (pNNR) were 52.9% in group-A and 69.4% in group-B. The ER-poor/HER2-positive subtype acquired the highest pNNR (79.6% in group-A and 87.9% in group-B, respectively) and the lowest rate of residual with ≥4 nodes involvement (1.9% and 3%, respectively) after PCrb plus trastuzumab. In multivariate analysis, trastuzumab added and ER-poor status were independent factors in predicting a higher pNNR in HER2-positive breast cancer. Forty-six tested patients showed that the ER-poor/HER2-positive subtype acquired a considerable high pNNR and axillary status with SLNB was well macthed with the axillary dissection.ER-poor/HER2-positive subtype of breast cancer is a potential candidate for undergoing sentinel lymph node biopsy instead of regional node dissection for accurate axillary evaluation after effective downstaging by neoadjuvant chemo-trastuzumab therapy.
- Published
- 2014
- Full Text
- View/download PDF
30. The Role of JAK-STAT-SOCS1 Axis in Tumorigenesis, Malignant Progression and Lymphatic Metastasis of Penile Cancer.
- Author
-
Da-Ming Xu, Ling-Xiao Chen, Xiao-Yu Zhuang, Hui Han, and Miao Mo
- Published
- 2024
- Full Text
- View/download PDF
31. The comparison of efficacy and safety evaluation of vacuum-assisted Elite 10-G system and the traditional BARD 14-G core needle in breast diagnosis: an open-label, parallel, randomized controlled trial
- Author
-
Ying Zhang, Junjie Li, Miao Mo, Juping Shen, Hui Ren, Shiping Li, Guangyu Liu, and Zhimin Shao
- Subjects
Surgery ,General Medicine - Published
- 2023
32. Epidemiological landscape of esophageal cancer in Asia: Results from <scp>GLOBOCAN</scp> 2020
- Author
-
Hongcheng Zhu, Zezhou Wang, Bingbin Deng, Miao Mo, Honggang Wang, Ke Chen, Haoxuan Wu, Ting Ye, Boyan Wang, Dashan Ai, Shennan Hao, Ihsuan Tseng, and Kuaile Zhao
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,General Medicine - Published
- 2023
33. All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits
- Author
-
Huai-liang Wu, Zi-yin Luo, Zong-lin He, Yue Gong, Miao Mo, Wai-kit Ming, and Guang-yu Liu
- Subjects
Cancer Research ,Oncology - Abstract
Background The OlympiA trial demonstrated the benefits of adjuvant usage of olaparib for high-risk patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) and germline BRCA (gBRCA) mutation. This provoked thoughts on the clinical criteria of gBRCA testing. This study aims to estimate the costs and benefits of gBRCA testing and adjuvant olaparib therapy for patients with triple-negative breast cancer (TNBC) and hormone-receptor (HR)-positive and HER2-negative BC in China and the United States of America (USA). Methods We used a Markov chain decision tree analytic model to compare three gBRCA screening policies in China and the USA: (1) no gBRCA testing; (2) selected gBRCA testing and (3) universal gBRCA testing for nonmetastatic TNBC and HR-positive HER2-negative BC patients. We modelled the benefit of systemic therapy and risk-reducing surgeries among patients identified with pathogenic or likely pathogenic variants (PVs) in BRCA1 and BRCA2. Results Changing from the selected gBRCA testing to the universal gBRCA testing in TNBC patients is cost-effective, with the incremental cost-effectiveness ratios (ICERs) being 10991.1 and 56518.2 USD/QALY in China and the USA, respectively. Expanding universal gBRCA testing to HR-positive HER2-negative BC and TNBC patients has ICERs of 2023.3 and 16611.1 USD/QALY in China and the USA, respectively. Discussion By performing gBRCA testing on all HER2-negative BC patients, adjuvant olaparib can be offered to high-risk patients with a PV in BRCA1 or BRCA2. These patients are also candidates for risk-reducing surgeries, an important aspect of their survivorship care, and these interventions can improve survival outcomes. With the willingness-to-pay thresholds being 31,500.0 and 100,000.0 USD per QALY gained in China and the USA, respectively, universal gBRCA testing is likely cost-effective for all HER2-negative BC patients. This simplified criterion of gBRCA testing for BC is recommended for adoption by current guidelines in China and the USA.
- Published
- 2022
34. Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study
- Author
-
Si-Yu Wu, Jian-Wei Li, Yu-Jie Wang, Kai-Rui Jin, Ben-Long Yang, Jun-Jie Li, Xiao-Li Yu, Miao Mo, Na Hu, Zhi-Ming Shao, and Guang-Yu Liu
- Subjects
Surgery ,General Medicine - Published
- 2023
35. The clinical significance of Zinc finger protein 2 in laryngeal squamous cell carcinoma and its potential mechanism
- Author
-
Caixing Lin, Miao Mo, Yong Liang, Suning Huang, Hua Ding, Li Jiang, Tingting Zhang, Yeying Fang, Dongmei Yan, Jiyun Wu, Yitong Niu, Xiaowei Wu, and Zhuxin Wei
- Abstract
Backgrand: Laryngeal squamous cell carcinoma (LSCC), which arises from the laryngeal mucosa, is the main type of laryngeal cancer. An influence of Zinc finger protein 2 (ZIC2) expression on the occurrence and progression of LSCC has not been established. We aim to identify the clinical importance of ZIC2 expression in LSCC and to explore its latent potential mechanisms. Methods:In this study, we studied the relationship between protein and mRNA expression of ZIC2 in LSCC and clinical pathological features and prognoses via mining the high-throughput sequencing data from multiple databases and to use immunohistochemistry (IHC) and integrated analysis. Meanwhile the downstream targets of ZIC2 transcription factor were also predicted with ChlP-seq data. The KEGG, GO and PPI analysis were applied to identified the potential mechanism of ZIC2 in LSCC. After constructing ZIC2 stable expression cells, we attempt to disclose an association between ZIC2 and cell cycle and apoptosis with RT-qPCR and Western blot methods. Cell cycle was detected by flow cytometry. Results: A higher ZIC2 expression in LSCC were found in both protein and mRNA level by integrated analysis (standard mean difference, SMD=1.76 (95% CI, 1.34–2.18)). The IHC staining of ZIC2 protein is nuclear in LSCC. Kinesin family member 14 (KIF14) was explored as the potential downstream target gene of ZIC2. ZIC2 has a binding peak before the transcription start site of KIF14 and their expression were positively correlated with each other. The expression of KIF14 was elevated after overexpressing ZIC2. The KEGG analysis revealed that ZIC2 may involve LSCC by cell cycle. Cell cycle testing revealed that in ZIC2 knockdown cells, G1 phase increased while S phase was decreased. After knockdown ZIC2 expression, the expression of P21 was elevated, Bax protein was increased while Bcl2 decreased. The analysis of the summary receiver operating characteristic (sROC) demonstrated that ZIC2 may have potential to become a diagnostic marker for LSCC. Conclusions: In conclusion, up-regulation of ZIC2 may contribute to LSCC pathogenesis in cell cycle pathway and it may target KIF14 in LSCC, but these need further research in the future.
- Published
- 2023
36. Comparison of Time-Varying Pattern of Recurrence in Chinese Breast Cancer Patients with Different Molecular Subtypes: A Single-Center Retrospective Study
- Author
-
Xujie Zhou, Yuting Sang, Jiajian Chen, Miao Mo, Jianjing Hou, Benlong Yang, and Jiong Wu
- Subjects
Oncology - Published
- 2022
37. Proton and Carbon Ion Radiation Therapy Decreased Severe Lymphopenia by Reducing Thoracic Vertebra and Aortic Doses in Non-small Cell Lung Cancer Versus Intensity Modulated Radiation Therapy
- Author
-
Yaqi Li, Xingwen Fan, Qi Yu, Haoyang Zhai, Miao Mo, Jiayao Sun, Jing Mi, Renquan Lu, Jingfang Mao, Jian Chen, Ningyi Ma, Wenxuan Yang, Ji Zhu, Guoliang Jiang, and Kailiang Wu
- Subjects
Cancer Research ,Radiation ,Oncology ,Radiology, Nuclear Medicine and imaging - Abstract
Lymphopenia is a common adverse effect of radiotherapy (RT). Little is known about the difference in lymphopenia between intensity-modulated (photon) radiation therapy (IMRT) and proton and carbon ion radiotherapy (PCIRT). This study aimed to investigate lymphopenia differences between IMRT and PCIRT in non-small cell lung cancer (NSCLC).Clinical and dosimetric parameters were collected from 343 patients who received definitive IMRT or PCIRT for NSCLC. Severe lymphopenia (SRL) was defined as an absolute lymphocyte count (ALC) ≤0.5*10Compared to the IMRT group, the PCIRT group was less likely to develop SRL (p0.001). Compared with non-SRL group, SRL group showed significant association with poorer OS, with median survival time of 29.2 vs. 15.0 months (p = 0.046). IMRT was an independent risk factor of SRL (p = 0.004). A lower ALC before RT (p = 0.030) and larger planning target volume (PTV) (p = 0.002) were also significant independent risk factors for SRL. Moreover, the majority of dosimetric parameters of organ at risks in PCIRT were lower than those in IMRT (p0.001). Thoracic vertebra V5 (p =0.002) and aorta V5 (p =0.026) were identified as independent risk predictors of SRL after adding dosimetric parameters to the regression model.Compared with IMRT, PCIRT could reduce the SRL incidence, possibly by limiting thoracic vertebra and aortic doses, and SRL was associated with poor outcomes in NSCLC patients.
- Published
- 2022
38. Delayed initiation of radiation therapy is associated with inferior outcomes for breast cancer patients with hormone receptor-negative tumors after breast-conserving surgery
- Author
-
Yizhou Shen, Yongxiang Qian, Genhong Di, Jie Chen, Zhi-Ming Shao, Zhebin Liu, Shuang Li, Zhaozhi Yang, Xiaoli Yu, Jiong Wu, Guangyu Liu, Yi-Zhou Jiang, Ke-Da Yu, Ding Ma, Sheng Chen, Miao Mo, Xiaoyan Ma, and Ying Zhang
- Subjects
medicine.medical_specialty ,Multivariate analysis ,business.industry ,medicine.medical_treatment ,Hazard ratio ,Urology ,medicine.disease ,Radiation therapy ,Breast cancer ,Hormone receptor ,Cohort ,medicine ,Breast-conserving surgery ,Original Article ,Surgery ,Cumulative incidence ,business - Abstract
BACKGROUND: To investigate whether the interval between adjuvant chemotherapy (CT) completion and postoperative radiation therapy initiation (ICR) after breast-conserving surgery (BCS) affects ipsilateral breast tumor recurrence (IBTR) or survival. METHODS: All women who were diagnosed with invasive breast cancer and underwent BCS between 2005 and 2014 were included. In total, 1,472 patients underwent adjuvant CT followed by postoperative radiation therapy (RT) (CT+), whereas 402 patients received postoperative RT alone (CT−). Analyses were stratified by ICR and the interval between surgery and the initiation of postoperative RT (ISR) in these two cohorts. The cutoff points for treatment delay were 47 days in the CT+ cohort and 69 days in the CT− cohort. IBTR, local-regional failure (LRF), disease-free survival (DFS), and overall survival (OS) were assessed through Kaplan-Meier (K-M) analysis. Univariate and multivariate regression analyses were performed to determine the prognostic factors of survival outcomes. RESULTS: The median follow-up duration was 56 months. There was an association between a delay in ICR and an increase in IBTR in the CT+ group (P=0.014 for intervals ≤47 vs. >47 days). This association was confirmed by multivariate analyses [hazard ratio (HR) of 2.766; P=0.046] in the hormone receptor-negative subgroup. The 5-year cumulative incidence rates of IBTR were 1.3% and 3.3% (≤47 vs. >47 days, respectively) in the CT+ cohort. For patients in the CT− cohort, a longer delay of initiation of postoperative RT (≤69 vs. >69 days) significantly decreased DFS (HR of 6.430; P=0.002). The 5-year cumulative incidence rates of disease recurrence were 3.0% for RT starting ≤69 days after surgery and 12.6% for RT starting >69 days after surgery. CONCLUSIONS: A high IBTR rate was related to an ICR beyond 47 days. Delay of RT after CT or surgery among patients who undergo BCS should be avoided, especially among patients in the hormone receptor-negative subgroup.
- Published
- 2021
39. WDHD1 is over-expressed in nasopharyngeal carcinoma and may control the expression of ITGAV
- Author
-
Ji‐Yun Wu, Yi‐Tong Niu, Su‐Ning Huang, Yu‐Min Tan, Zhen‐Dong Yang, Ye‐Ying Fang, Li Jiang, Ting‐Ting Zhang, Xiao‐Fen Zeng, Yun‐Xi Peng, Miao Mo, Cai‐Xing Lin, and Zhu‐Xin Wei
- Subjects
General Biochemistry, Genetics and Molecular Biology - Abstract
Nasopharyngeal carcinoma (NPC) is a highly metastatic and invasive malignant tumor that originates in the nasopharynx. The DNA-binding protein WD repeat and HMG-box DNA-binding protein 1 (WDHD1) are highly expressed in a variety of tumours, but its expression and mechanism of action in NPC have not been reported to date. To investigate the involvement of WDHD1 in NPC, we first mined databases for the gene expression profile of NPC. Immunohistochemistry (IHC) was performed on 338 cases of NPC and 112 non-NPC samples to verify the results. We report that the expression of WDHD1 is significantly elevated in NPC. ChIP-seq was used to show that integrin alpha V (ITGAV) and WDHD1 exhibit a significant binding peak in the promoter region of the ITGAV gene. The expression levels of ITGAV and WDHD1 exhibit a significant positive correlation, and IHC was performed to show that ITGAV is highly expressed in NPC. Expression of ITGAV increased after overexpression of WDHD1, suggesting that ITGAV may be a potential target gene of WDHD1. Pathway analysis showed that both genes were closely related to the cell cycle, and flow cytometry was used to further confirm that decreased expression of WDHD1 significantly increased the number of apoptotic cells. In conclusion, our results suggest that expression of WDHD1 is increased in NPC and is likely to be associated with the NPC cell cycle; thus, we propose that WDHD1 may have the potential as a target gene for primary screening and treatment of NPC.
- Published
- 2022
40. Dichotomous cis-regulatory motifs mediate the maturation of the neuromuscular junction by retrograde BMP signaling
- Author
-
Vuilleumier, Robin, primary, Miao, Mo, additional, Medina-Giro, Sonia, additional, Ell, Clara-Maria, additional, Flibotte, Stephane, additional, Lian, Tianshun, additional, Kauwe, Grant, additional, Collins, Annie, additional, Ly, Sophia, additional, Pyrowolakis, George, additional, Haghighi, A Pejmun, additional, and Allan, Douglas W, additional
- Published
- 2022
- Full Text
- View/download PDF
41. Time‐varying effect of sex on prognosis of lung adenocarcinoma surgical patients in China
- Author
-
Jie Shen, Miao Mo, Yang Zhang, Ying Zheng, Zezhou Wang, Ting Ye, Changming Zhou, Haiquan Chen, Hong Hu, and Xiaoshuang Feng
- Subjects
Adult ,Male ,0301 basic medicine ,Pulmonary and Respiratory Medicine ,China ,medicine.medical_specialty ,Lung Neoplasms ,Time Factors ,Adenocarcinoma of Lung ,Subgroup analysis ,03 medical and health sciences ,Sex Factors ,0302 clinical medicine ,Internal medicine ,Humans ,Medicine ,sex ,time‐dependent effect ,Stage (cooking) ,inverse probability of treatment weighting ,Pathological ,RC254-282 ,Aged ,Aged, 80 and over ,adenocarcinoma ,business.industry ,Proportional hazards model ,Confounding ,Hazard ratio ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Original Articles ,General Medicine ,Middle Aged ,medicine.disease ,Survival Analysis ,Treatment Outcome ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Propensity score matching ,Adenocarcinoma ,Original Article ,Female ,prognosis ,business - Abstract
Background Little is known about the prognostic advantage of sex for pulmonary adenocarcinoma among Chinese patients. In this study, we aimed to investigate the true sex differences in prognosis by adjusting for confounders and to explore whether the differences were time‐varying. Methods We identified 4438 lung adenocarcinoma patients who underwent surgery at a regional Cancer Center of China from 2008 to 2016, retrospectively. Sex, age group, smoking history, year of diagnosis and pathological stage were collected. Time‐dependent Cox regression models with inverse probability of treatment weighting (IPTW) based on propensity score were used to assess the effect of sex and account for confounders. Landmark analyses were conducted to assess survival before, and after, five years. Results Of these patients, 1761 (39.7%) were men and 2677 (60.3%) were women. Median follow‐up time was 52.6 months. After IPTW adjustment, women were found to have significantly better survival than men varying with time in both crude and IPTW models (hazard ratio [HR] [t] = 0.453*1.015t, where t is the length of time from treatment and its unit is month, p, We analyzed the long‐term survival results of lung adenocarcinoma surgical patients from a large single‐center in China. The survival advantage of women lung adenocarcinoma surgical patients over men is time‐varying. Compared with men, women had better survival after surgical resection of lung adenocarcinoma within five years, especially those who were older, heavy‐smokers and pathological stage 0–IB, but with no significant difference in survival after five years or even in some cases the results in women were inferior to men.
- Published
- 2021
42. Assessing Individual Risk for High-Risk Early Colorectal Neoplasm for Pre-Selection of Screening in Shanghai, China: A Population-Based Nested Case–Control Study
- Author
-
Ying Zheng, Guoxiang Cai, Fei Liang, Miao Mo, Changming Zhou, Meiying Zhu, Yiling Wu, Zezhou Wang, Binxin Cai, Xiaoshuang Feng, and Jie Shen
- Subjects
0301 basic medicine ,Population ,colorectal cancer ,Logistic regression ,03 medical and health sciences ,0302 clinical medicine ,risk model ,Medicine ,education ,Original Research ,education.field_of_study ,Cancer prevention ,cancer prevention ,Receiver operating characteristic ,business.industry ,screening ,Regression analysis ,030104 developmental biology ,Oncology ,Cancer Management and Research ,030220 oncology & carcinogenesis ,Cohort ,Nested case-control study ,business ,Body mass index ,Demography - Abstract
Jie Shen,1,2,* Yiling Wu,3,* Xiaoshuang Feng,1,2,* Fei Liang,4 Miao Mo,1,2 Binxin Cai,3 Changming Zhou,1,2 Zezhou Wang,1,2 Meiying Zhu,3 Guoxiang Cai,2,5 Ying Zheng1,2 1Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China; 3Department of Noninfectious Chronic Disease Control and Prevention, Songjiang District Center for Disease Control and Prevention, Shanghai, People’s Republic of China; 4Department of Biostatistics, Zhongshan Hospital Fudan University, Shanghai, People’s Republic of China; 5Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Ying ZhengDepartment of Cancer Prevention, Fudan University Shanghai Cancer Center, No. 270 Dong’An Road, Shanghai, 200032, People’s Republic of ChinaEmail zhengying@fudan.edu.cnObjective: To identify people with high-risk early colorectal neoplasm is highly desirable for pre-selection in colorectal cancer (CRC) screening in low-resource countries. We aim to build and validate a risk-based model so as to improve compliance and increase the benefits of screening.Patients and Methods: Using data from the Shanghai CRC screening cohort, we conducted a population-based nested case–control study to build a risk-based model. Cases of early colorectal neoplasm were extracted as colorectal adenomas and stage 0-I CRC. Each case was matched with five individuals without neoplasm (controls) by the screening site and year of enrollment. Cases and controls were then randomly divided into two groups, with two thirds for building the risk prediction model and the other one third for model validation. Known risk factors were included for risk prediction models using logistic regressions. The area under the receiver operating characteristic curve (AUC) and Hosmer–Lemeshow chi-square statistics were used to evaluate model discrimination and calibration. The predicted individual risk probability was calculated under the risk regression equation.Results: The model incorporating age, sex, family history and lifestyle factors including body mass index (BMI), smoking status, alcohol, regular moderate-to-intensity physical activity showed good calibration and discrimination. When the risk cutoff threshold was defined as 17%, the sensitivity and specificity of the model were 63.99% and 53.82%, respectively. The validation data analysis also showed well discrimination.Conclusion: A risk prediction model combining personal and lifestyle factors was developed and validated for high-risk early colorectal neoplasm among the Chinese population. This risk-based model could improve the pre-selection for screening and contribute a lot to efficient population-based screening in low-resource countries.Keywords: cancer prevention, colorectal cancer, risk model, screening
- Published
- 2021
43. Comparison of time-varying recurrence patterns in breast cancer patients with different molecular subtypes treated from 2008 to 2012 and from 2013 to 2016: a single-center retrospective study
- Author
-
Xu-jie Zhou, Yu-ting Sang, Jia-jian Chen, Miao Mo, Jian-jing Hou, Ben-long Yang, and Jiong Wu
- Abstract
Purpose: To compare the time-varying recurrence patterns of different molecular subtypes of breast cancer in the contemporary era with those in the past era. Methods: This retrospective study included 14627 consecutive invasive breast cancer patients who underwent surgery from 2008 to 2016 at Fudan University Shanghai Cancer Center. We defined the period from 2013 to 2016 as the contemporary era and that from 2008 to 2012 as the past era. Five subtypes were defined according to the immunohistochemistry results. Emphasis was made on the changing patterns of recurrence for patients with different molecular subtypes changed between the two treatment eras. Kaplan–Meier survival curves were generated, and the hazard function was used to estimate the annual recurrence hazard. Results: By the end of follow-up (median, 68.1 months), 1429 patients (9.77%) experienced recurrence and metastasis. The annual recurrence risks of the entire population and each molecular type in 2013-2016 were reduced compared with those in 2008-2012. Luminal A and triple-negative patients in 2013-2016 showed a significantly lower recurrence hazard curve than those in 2008-2012. The recurrence hazard curve of luminal B (HER2-) and HER2+ subtypes was lower in 2013-2016 than in 2008-2012. The recurrence risk of the luminal B (HER2+) subtype was reduced substantially during 2013-2016, showing a delay of two years.Conclusion: With early detection of disease recurrence and improved treatment strategies, the recurrence patterns of different molecular subtypes of breast cancer have changed. The time-varying recurrence patterns observed during the contemporary era are significant for treatment decision-making and clinical trial planning.
- Published
- 2022
44. Cyclophosphamide-Free Adjuvant Chemotherapy for Ovarian Protection in Young Women With Breast Cancer: A Randomized Phase 3 Trial
- Author
-
Ke-Da Yu, Miao Mo, Min He, Zhi-Ming Shao, Jing-Yu Ge, Spectrum Investigators, and Xi-Yu Liu
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Paclitaxel ,medicine.medical_treatment ,Population ,Breast Neoplasms ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Pregnancy ,Interquartile range ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,030212 general & internal medicine ,education ,Cyclophosphamide ,Epirubicin ,education.field_of_study ,Chemotherapy ,Intention-to-treat analysis ,business.industry ,Editorials ,medicine.disease ,Chemotherapy regimen ,Regimen ,Treatment Outcome ,Oncology ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Female ,business ,medicine.drug - Abstract
Background Chemotherapy-induced premature menopause leads to some consequences, including infertility. We initiated this randomized phase III trial to determine whether a cyclophosphamide-free adjuvant chemotherapy regimen would increase the likelihood of menses resumption and improve survival outcomes. Methods Young women with operable estrogen receptor-positive HER2-negative breast cancer after definitive surgery were randomly assigned to receive adjuvant epirubicin and cyclophosphamidefollowed by weekly paclitaxel (EC-wP) or epirubicin and paclitaxel followed by weekly paclitaxel (EP-wP). All patients received at least 5-year adjuvant endocrine therapy after chemotherapy. Two coprimary endpoints were the rate of menstrual resumption at 12 months after chemotherapy and 5-year disease-free survival in the intention-to-treat population. This study is registered at ClinicalTrials.gov (NCT01026116). All statistical tests were 2-sided. Results Between January 2011 and December 2016, 521 patients (median age = 34 years; interquartile range = 31-38 years) were enrolled, with 261 in the EC-wP group and 260 in the EP-wP group. The rate of menstrual resumption at 12 months after chemotherapy was 48.3% in EC-wP (95% confidence interval [CI] = 42.2% to 54.3%) and 63.1% in EP-wP (95% CI = 57.2% to 68.9%), with an absolute difference of 14.8% (95% CI = 6.37% to 23.2%, P Conclusions The cyclophosphamide-free chemotherapy regimen might be associated with a higher probability of menses resumption.
- Published
- 2021
45. Identification of key genes and microRNA regulatory network in development and progression of urothelial bladder carcinoma
- Author
-
Xiheng Hu, Yangle Li, Long Wang, Miao Mo, Xiongbing Zu, and Wei He
- Subjects
0301 basic medicine ,Bladder cancer ,biology ,Urology ,Cancer ,medicine.disease ,medicine.disease_cause ,Transcriptome ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Reproductive Medicine ,030220 oncology & carcinogenesis ,microRNA ,Carcinoma ,medicine ,biology.protein ,Cancer research ,PTEN ,Original Article ,KRAS ,KEGG - Abstract
Background Bladder cancer as other cancers contains multiple dynamic alterations in progression. Theoretically, large number of genes participates in cancer progression. In the present study, the interconnections of genesets defined by Gene Set Enrichment Analysis (GSEA) and tumor histopathological stages were characterized. In addition, the outcomes with genesets were discussed in bladder cancer. Methods Transcriptome data from 411 tissues of urothelial bladder carcinoma and 19 samples from adjacent tissues were retrieved from The Cancer Genome Atlas (TCGA) database. Single-sample GSEA (ssGSEA), cluster analysis of geneset enrichment scores and genesets as indicators in prognosis were applied to elucidate the correlations between genesets and bladder cancer progression. Results Chemical and genetic perturbations (CGP), canonical pathways (CP), CP:BIOCARTA (BioCarta gene sets), CP:KEGG (KEGG gene sets) and CP:REACTOME (Reactome gene sets) in C2 collection, upstream cis-regulatory motifs serum response factor (SRF) in C3 collection, KRAS in C6 collection and C8+ T cells in C7 collection were observed as enriched by ssGSEA. The cluster 2 identified from cluster analysis shows a more immune active microenvironment which tended to increase in stage II and decreased in stage IV indicating the crucial role in bladder cancer progression. miR-450, miR-518s, transcription factor PAX3, KRAS and PTEN were potential markers for outcomes of urothelial bladder carcinoma. Activating tumor immune microenvironment had deteriorated prognosis of patients with bladder cancer. Conclusions Our findings demonstrated that activating tumor immune microenvironment is a negative factor for outcomes of urothelial bladder carcinoma. These data provided a potential combination strategy for patients with bladder cancer.
- Published
- 2021
46. Long noncoding RNA MAFG-AS1 facilitates bladder cancer tumorigenesis via regulation of miR-143-3p/SERPINE1 axis
- Author
-
Wei He, Cheng Zhao, Miao Mo, Xiheng Hu, Yangle Li, Cai Yi, and Xi Sun
- Subjects
MAFG-AS1 ,Cancer Research ,Bladder cancer ,miR-143-3p ,Biology ,medicine.disease_cause ,medicine.disease ,Long non-coding RNA ,tumorigenesis ,Oncology ,Mir 143 3p ,medicine ,Cancer research ,Original Article ,Radiology, Nuclear Medicine and imaging ,Carcinogenesis ,SERPINE1 - Abstract
Background Numerous studies have shown that long noncoding RNAs (lncRNAs) act as key regulators of bladder cancer progression. While lncRNA MAFG-AS1 has been confirmed as an oncogenic molecule in various cancers and tumorigenesis, in present study, we investigated its function and role in the tumorigenesis of bladder cancer. Methods The expression of MAFG-AS1, miR-143-3p and SERPINE1 in bladder cancer tissues was detected by qRT-PCR methods. The relationship between MAFG-AS1 expression and clinicopathologic characteristics of bladder cancer was analyzed. The effects of MAFG-AS1 depletion on cell proliferation, migration, invasion and apoptosis were investigated. The binding relationship of MAFG-AS1, miR-143-3p and SERPINE1 was examined by luciferase reporter analysis and RNA immunoprecipitation (RIP) assay. Results MAFG-AS1 was upregulated in bladder cancer tissues and cell lines. High MAFG-AS1 expression was associated with bladder cancer histological grade, TNM stage and lymph node metastasis, and patients with high expression showed poor overall survival. Cell function experiments showed that MAFG-AS1 silencing markedly suppressed bladder cancer cell proliferation, migration, invasion and increased cell apoptosis. Moreover, our results demonstrated that MAFG-AS1 functioned as a competing endogenous RNA for miR-143-3p to modulate SERPINE1 levels. Further analysis showed that miR-143-3p inhibition or SERPINE1 overexpression alleviated the suppressive effects of MAFG-AS1 silencing on malignant features. Conclusions Our findings indicated that MAFG-AS1 facilitates tumorigenesis via regulation of the miR-143-3p/SERPINE1 axis and also provides a novel insight into tumorigenesis and identify a promising therapeutic target for bladder cancer.
- Published
- 2020
47. Changes of serum metabolites levels during neoadjuvant chemoradiation and prediction of the pathological response in locally advanced rectal cancer
- Author
-
Jiali Lv, Huixun Jia, Miao Mo, Jing Yuan, Zhenyu Wu, Shuai Zhang, Fan Zhe, Bingbing Gu, Bingbing Fan, Chunxia Li, Tao Zhang, and Ji Zhu
- Subjects
Rectal Neoplasms ,Endocrinology, Diabetes and Metabolism ,Clinical Biochemistry ,Metabolome ,Humans ,Metabolomics ,Biochemistry ,Glycerylphosphorylcholine ,Neoadjuvant Therapy ,Acetylcholine - Abstract
Previous studies have explored prediction value of serum metabolites in neoadjuvant chemoradiation therapy (NCRT) response for rectal cancer. To date, limited literature is available for serum metabolome changes dynamically through NCRT.This study aimed to explore temporal change pattern of serum metabolites during NCRT, and potential metabolic biomarkers to predict the pathological response to NCRT in locally advanced rectal cancer (LARC) patients.Based on dynamic UHPLC-QTOF-MS untargeted metabolomics design, this study included 106 LARC patients treated with NCRT. Biological samples of the enrolled patients were collected in five consecutive time-points. Untargeted metabolomics was used to profile serum metabolic signatures from LARC patients. Then, we used fuzzy C-means clustering (FCM) to explore temporal change patterns in metabolites cluster and identify monotonously changing metabolites during NCRT. Repeated measure analysis of variance (RM-ANOVA) and multilevel partial least-squares discriminant analysis (ML-PLS-DA) were performed to select metabolic biomarkers. Finally, a panel of dynamic differential metabolites was used to build logistic regression prediction models.Metabolite profiles showed a clearly tendency of separation between different follow-up panels. We identified two clusters of 155 serum metabolites with monotonously changing patterns during NCRT (74 decreased metabolites and 81 increased metabolites). Using RM-ANOVA and ML-PLS-DA, 8 metabolites (L-Norleucine, Betaine, Hypoxanthine, Acetylcholine, 1-Hexadecanoyl-sn-glycero-3-phosphocholine, Glycerophosphocholine, Alpha-ketoisovaleric acid, N-Acetyl-L-alanine) were further identified as dynamic differential biomarkers for predicting NCRT sensitivity. The area under the ROC curve (AUC) of prediction model combined with the baseline measurement was 0.54 (95%CI = 0.43 ~ 0.65). By incorporating the variability indexes of 8 dynamic differential metabolites, the prediction model showed better discrimination performance than baseline measurement, with AUC = 0.67 (95%CI 0.57 ~ 0.77), 0.64 (0.53 ~ 0.75), 0.60 (0.50 ~ 0.71), and 0.56 (0.45 ~ 0.67) for the variability index of difference, linear slope, ratio, and standard deviation, respectively.This study identified eight metabolites as dynamic differential biomarkers to discriminate NCRT-sensitive and resistant patients. The changes of metabolite level during NCRT show better performance in predicting NCRT sensitivity. These findings highlight the clinical significance of metabolites variabilities in metabolomics analysis.
- Published
- 2022
48. Early warning of enterprise decline in a life cycle using neural networks and rough set theory.
- Author
-
Yu Cao, Xiaohong Chen 0001, Desheng Dash Wu, and Miao Mo
- Published
- 2011
- Full Text
- View/download PDF
49. MEST promotes bladder cancer cell proliferation, migration and invasion via STAT3/Twist-1-mediated EMT
- Author
-
Miao Mo, Long Wang, Shiyu Tong, Yangle Li, Wei He, Xiheng Hu, and Cheng Zhao
- Subjects
Cancer Research ,STAT3/Twist-1 signalling ,biology ,Chemistry ,Bladder cancer cell ,epithelial-mesenchymal transition ,bladder cancer (BC) ,Oncology ,biology.protein ,Cancer research ,Original Article ,Radiology, Nuclear Medicine and imaging ,Twist ,STAT3 ,Mesoderm-specific transcript (MEST) - Abstract
Background Mesoderm-specific transcript (MEST) has been demonstrated to be a proto-oncogene or anti-oncogene in various carcinomas. However, the role and mechanism of MEST in bladder cancer (BC) are still unknown. Here we aimed to explore the effect of MEST on malignant biological behaviour in BC and its potential mechanism. Methods The expression of MEST in BC tissues and cells was detected by qRT-PCR methods. MEST depletion and overexpression cell lines were established in T24 and 5637 respectively. Then the effects of MEST on cell proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) were investigated. Finally, the STAT3/Twist-1 signaling was verified. Results MEST was elevated in BC tissues and cells lines, and its high expression was highly relevant to the clinicopathologic features of patients with BC and to poor prognosis in these patients. MEST depletion impeded cell proliferation, migration and invasion as well as epithelial-mesenchymal transition (EMT), while MEST overexpression promoted malignant biological behaviour in BC. Mechanistically, MEST upregulated p-STAT3 and Twist-1 expression, while treatment with a STAT3 inhibitor clearly attenuated the STAT3 activation and Twist-1 upregulation induced by MEST. Subsequently, rescue assays confirmed that inhibition of STAT3 signalling could remarkably relieve the oncogenic effects of MEST on malignant biological behaviour in BC. Conclusions Our data confirmed that MEST exerts oncogenic functions in bladder cancer via STAT3/Twist-1 signalling and that MEST may represent a promising target in BC treatment.
- Published
- 2020
50. Serum CXCL13 Level is Associated with Tumor Progression and Unfavorable Prognosis in Penile Cancer
- Author
-
Shiyu Tong, Xiheng Hu, Xiongbing Zu, Miao Mo, and Tao Li
- Subjects
0301 basic medicine ,Chemokine ,MMP2 ,biology ,Cell growth ,business.industry ,medicine.disease ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,Tumor progression ,030220 oncology & carcinogenesis ,medicine ,Cancer research ,biology.protein ,Penile cancer ,Pharmacology (medical) ,Cancer biomarkers ,CXCL13 ,Autocrine signalling ,business - Abstract
Background Chemokine (C-X-C motif) ligands (CXCLs) are important regulators of tumor progression in many cancers and could serve as potential cancer biomarkers. However, the expression patterns as well as functions of CXCLs remain unclear in penile cancer (PC). The aim of this study was to evaluate the usefulness of serum CXCL13 as a potential cancer biomarker for PC. Patients and Methods This retrospective study enrolled 76 patients diagnosed with PC between 2016 and 2018. Serum CXCL13 level was detected by enzyme-linked immunosorbent assay. Univariable and multivariable Cox regression analyses were conducted to identify the prognostic factors that influence disease-free survival. Human penile cancer cell lines Penl1, Penl2, 149RCa and LM156 were used as in vitro models. The expression of CXCL13 protein in PC cell lines was analyzed by Western blotting. Results Our initial analysis on GSE57955 dataset identified CXCL13 as a top CXCL gene enriched in PC. Higher preoperative serum CXCL13 level was detected in PC cohorts than in healthy male controls (P
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.